Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma

Cancer Gene Therapy volume 23, pages 371–372 (2016)Cite this article

Subjects

Abstract

Neuroblastoma (NB) is known as a pediatric neoplasm that is associated with variable histopathological features. The use of biomarkers contributes to the monitoring and treatment of various malignancies such as NB. The identification of novel biomarkers such as (epi)genetic biomarkers and microRNAs (miRNAs) in NB has led to better treatments of NB. Among them, miRNAs have emerged as powerful tools in diagnosis, prognosis and therapeutic biomarkers for patients with NB. Circulating biomarkers such as circulating miRNAs present in body fluids (for example, plasma, serum and urine) provided an interesting field of study in NB treatment. The miRNAs have central roles in different pathogenic events in various malignancies such as NB. Hence, these molecules can be a suitable candidate for monitoring and treating NB patients. Here, we summarize some miRNAs as potential prognosis, diagnosis and therapeutic biomarkers in NB.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Zhu S, Lee J-S, Guo F, Shin J, Perez-Atayde AR, Kutok JL et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 2012; 21: 362–373.

    Article  CAS  Google Scholar 

  2. Brodeur GM . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203–216.

    Article  CAS  Google Scholar 

  3. Gholamin S, Pasdar A, Sadegh Khorrami M, Mirzaei H, Reza Mirzaei H, Salehi R et al. The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment. Curr Pharm Des 2016; 22: 397–403.

    Article  CAS  Google Scholar 

  4. Mirzaei H, Gholamin S, Shahidsales S, Sahebkar A, Jafaari MR, Mirzaei HR et al. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur J Cancer 2016; 53: 25–32.

    Article  CAS  Google Scholar 

  5. Simonian M, Mosallayi M, Mirzaei H . Circulating miR-21 as novel biomarker in gastric cancer: diagnostic and prognostic biomarker. J Cancer Res Ther 2016. (e-pub ahead of print).

  6. Reza Mirzaei H . Circulating microRNAs in hepatocellular carcinoma: potential diagnostic and prognostic biomarkers. Curr Pharm Des 2016. (e-pub ahead of print).

  7. Salarini R, Sahebkar A, Mirzaei H, Jaafari M, Riahi M, Hadjati J et al. Epi-drugs and epi-miRs: moving beyond current cancer therapies. Curr Cancer Drug Targets 2015. (e-pub ahead of print; 6 December 2015).

  8. Ghossein RA, Bhattacharya S, Rosai J . Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res 1999; 5: 1950–1960.

    CAS  PubMed  Google Scholar 

  9. Ramraj SK, Pandian V, Khan FH, Aravindan S, Herman TS, Natarajan M et al. Profiling of circulating miRNAs is a critical prognostic biomarker tool for high-risk neuroblastoma. Cancer Res 2014; 74: 5229.

    Article  Google Scholar 

  10. Combaret V, Bergeron C, Bréjon S, Iacono I, Perol D, Négrier S et al. Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett 2005; 228: 91–96.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hepatitis Research Center and Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran

    M Mohammadi

  2. Department of Biosystems, Faculty of Bioscience Engineering, Katholieke Universiteit Leuven—KU Leuven, Heverlee, Belgium

    M Goodarzi

  3. Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

    M R Jaafari

  4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    H R Mirzaei

  5. Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    H Mirzaei

Authors
  1. M Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Goodarzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M R Jaafari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H R Mirzaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Mirzaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to H R Mirzaei or H Mirzaei.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohammadi, M., Goodarzi, M., Jaafari, M. et al. Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma. Cancer Gene Ther 23, 371–372 (2016). https://doi.org/10.1038/cgt.2016.45

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2016.45

Search

Advanced search

Quick links